Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|February 15, 2021
- Ophthalmology Times: February 1, 2021
- Volume 46
- Issue 2
Improving practice office acoustics
Author(s)Jon Carter
Check out the latest cartoon!
Advertisement
Articles in this issue
over 5 years ago
Do you 'need' or just 'want' that new diagnostic imaging device?over 5 years ago
Noninvasive angiography with OCT offers definite valueover 5 years ago
Ophthalmology residents retrained as palliative care extendersover 5 years ago
How AAOOP is taking the pandemic by the hornsover 5 years ago
EyePod: Ophthalmologist shares Holocaust survival storyover 5 years ago
Investigators examine anti-VEGF medications in cases with ROPAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves subcutaneous Enspryng for TED
2
OT Roundup: Optogenetics Nobel Prize, BRUNELLO, DRAGON, eye transplant
3
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
4
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
5